CA1156148A - Traitement de la depression - Google Patents

Traitement de la depression

Info

Publication number: CA1156148A
Authority: CA; Canada
Prior art keywords: tyrosine; brain; levels; norepinephrine; composition
Prior art date: 1979-08-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000354019A

Other languages

English (en)

Inventor

Richard J. Wurtman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Massachusetts Institute of Technology

Original Assignee

Massachusetts Institute of Technology

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-08-13

Filing date

1980-06-13

Publication date

1983-11-01

1980-06-13 Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology

1983-11-01 Application granted granted Critical

1983-11-01 Publication of CA1156148A publication Critical patent/CA1156148A/fr

Status Expired legal-status Critical Current

Links

238000000034 method Methods 0.000 title description 7
230000008569 process Effects 0.000 title description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 93
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 93
210000004556 brain Anatomy 0.000 claims abstract description 76
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims abstract description 39
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims abstract description 39
229960002748 norepinephrine Drugs 0.000 claims abstract description 39
150000001413 amino acids Chemical class 0.000 claims abstract description 32
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 28
239000000203 mixture Substances 0.000 claims abstract description 26
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 16
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 16
210000000225 synapse Anatomy 0.000 claims abstract description 16
229940076279 serotonin Drugs 0.000 claims abstract description 14
230000007935 neutral effect Effects 0.000 claims abstract description 13
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 11
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 11
229940079593 drug Drugs 0.000 claims abstract description 11
239000003814 drug Substances 0.000 claims abstract description 11
230000002474 noradrenergic effect Effects 0.000 claims abstract 2
230000005062 synaptic transmission Effects 0.000 claims abstract 2
150000001875 compounds Chemical class 0.000 claims description 4
239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 3
229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims description 2
229940123445 Tricyclic antidepressant Drugs 0.000 claims description 2
239000003029 tricyclic antidepressant agent Substances 0.000 claims description 2
230000037058 blood plasma level Effects 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
230000001965 increasing effect Effects 0.000 abstract description 20
230000007423 decrease Effects 0.000 abstract description 8
230000003247 decreasing effect Effects 0.000 abstract description 6
230000001537 neural effect Effects 0.000 abstract description 4
230000001105 regulatory effect Effects 0.000 abstract description 3
229960004441 tyrosine Drugs 0.000 description 85
235000002374 tyrosine Nutrition 0.000 description 85
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 30
229940024606 amino acid Drugs 0.000 description 27
235000001014 amino acid Nutrition 0.000 description 27
241001465754 Metazoa Species 0.000 description 21
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 16
229960003081 probenecid Drugs 0.000 description 16
241000700159 Rattus Species 0.000 description 15
229960003638 dopamine Drugs 0.000 description 15
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 14
229960004502 levodopa Drugs 0.000 description 13
238000011282 treatment Methods 0.000 description 11
238000002474 experimental method Methods 0.000 description 9
235000005911 diet Nutrition 0.000 description 8
230000037213 diet Effects 0.000 description 8
210000002569 neuron Anatomy 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 7
239000005018 casein Substances 0.000 description 7
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 7
235000021240 caseins Nutrition 0.000 description 7
235000012054 meals Nutrition 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000009825 accumulation Methods 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
239000003085 diluting agent Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
FBWPWWWZWKPJFL-UHFFFAOYSA-N 3-Methoxy-4-hydroxyphenylethyleneglycol Chemical compound COC1=CC(C(O)CO)=CC=C1O FBWPWWWZWKPJFL-UHFFFAOYSA-N 0.000 description 4
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
239000002858 neurotransmitter agent Substances 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
230000000946 synaptic effect Effects 0.000 description 4
230000007306 turnover Effects 0.000 description 4
239000004474 valine Substances 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 3
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
208000020401 Depressive disease Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000001490 effect on brain Effects 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
150000002871 norepinephrines Chemical class 0.000 description 2
150000002990 phenothiazines Chemical class 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
PYVRVRFVLRNJLY-KTKRTIGZSA-N 1-oleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COP(O)(=O)OCCN PYVRVRFVLRNJLY-KTKRTIGZSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
206010007733 Catabolic state Diseases 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 1
102100033156 Dopamine beta-hydroxylase Human genes 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
102000010909 Monoamine Oxidase Human genes 0.000 description 1
108010062431 Monoamine oxidase Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
241000220317 Rosa Species 0.000 description 1
MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
235000018087 Spondias lutea Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
229960001570 ademetionine Drugs 0.000 description 1
230000004075 alteration Effects 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229910001863 barium hydroxide Inorganic materials 0.000 description 1
MVYYDFCVPLFOKV-UHFFFAOYSA-M barium monohydroxide Chemical compound [Ba]O MVYYDFCVPLFOKV-UHFFFAOYSA-M 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
150000005693 branched-chain amino acids Chemical class 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
230000002925 chemical effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000008645 cold stress Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
201000008980 hyperinsulinism Diseases 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
-1 leucine Chemical class 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
238000009790 rate-determining step (RDS) Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
230000037351 starvation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
230000008733 trauma Effects 0.000 description 1
238000007492 two-way ANOVA Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229910000368 zinc sulfate Inorganic materials 0.000 description 1

Landscapes

Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA000354019A 1979-08-13 1980-06-13 Traitement de la depression Expired CA1156148A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6615879A	1979-08-13	1979-08-13
US066,158		1979-08-13

Publications (1)

Publication Number	Publication Date
CA1156148A true CA1156148A (fr)	1983-11-01

Family

ID=22067622

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000354019A Expired CA1156148A (fr)	1979-08-13	1980-06-13	Traitement de la depression

Country Status (1)

Country	Link
CA (1)	CA1156148A (fr)

1980
- 1980-06-13 CA CA000354019A patent/CA1156148A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2000-11-01	MKEX	Expiry

Publication	Publication Date	Title
US4377595A (en)	1983-03-22	Process for reducing depression
Birkmayer et al.	1977	Implications of combined treatment with'Madopar'and L-deprenil in Parkinson's disease: a long-term study
Hadjiconstantinou et al.	1993	Aromatic L‐amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors
Oh et al.	1998	Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration
Birkmayer et al.	1975	The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil
US6706764B2 (en)	2004-03-16	Use of creatine or creatine analogs for the treatment of diseases of the nervous system
US4296119A (en)	1981-10-20	Process and composition for reducing blood pressure in animals
JP2000505426A (ja)	2000-05-09	神経細胞機能の維持、その消失の防止又は回復のためのデプレニル化合物の利用
Jacoby et al.	1976	Mechanisms by which quipazine, a putative serotonin receptor agonist, alters brain 5-hydroxyindole metabolism
WO2000007575A2 (fr)	2000-02-17	Procedes et compositions servant a augmenter la sensibilite a l'insuline
EP2310003A1 (fr)	2011-04-20	Inhibiteurs de la carnitine palmitoyltransférase-1 pour le traitement et la prévention de troubles provoqués par une délipidation du tissu nerveux
Lyles et al.	1982	In vitro and in vivo inhibition by benserazide of clorgyline-resistant amine oxidases in rat cardiovascular tissues
Kanazawa	1994	Short review on monoamine oxidase and its inhibitors
CA1140859A (fr)	1983-02-08	Procede et formule pour accroitre les concentrations de dopamine et de norepinephrine au niveau des synapses neurales
Simpkins et al.	1985	Direct evidence for brain-specific release of dopamine from a redox delivery system
US4397866A (en)	1983-08-09	Process for increasing glycine levels in the brain and spinal cord
US4435424A (en)	1984-03-06	Process for improving vigor and mood in normal human patients
Alonso et al.	1980	Tyrosine loading enhances catecholamine excretion by rats
US4190672A (en)	1980-02-26	Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
NO312812B1 (no)	2002-07-08	Anvendelse av preventivt eller terapeutisk medikament for sykdommen Alzheimer eller senildemens
CA1156148A (fr)	1983-11-01	Traitement de la depression
EP0005333B1 (fr)	1982-04-07	Composition pharmaceutique contenant un amino-acide pour réduire le taux de prolactine dans le sérum sanguin
US4224343A (en)	1980-09-23	Process and composition for decreasing blood serum prolactin levels
US4327112A (en)	1982-04-27	Process for increasing blood pressure
Hingtgen et al.	1975	Behavioral depression in pigeons following L-tryptophan administration